Background: Many infections due to Gram-positive cocci (GPC; staphylococci, streptococci and enterococci) regularly involve prolonged systemic antibiotic use. Dalbavancin has demonstrated activity against GPC isolates and has been approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults.
Introduction
Gram-positive cocci (GPC; staphylococci, streptococci and enterococci) are among the most important causes of both communityand hospital-associated infections. [1] [2] [3] [4] [5] [6] In addition to the innate virulence exhibited by pathogens such as Staphylococcus aureus and Streptococcus pneumoniae, 2, 3, 7, 8 GPC are notable for the ability to acquire and express numerous antimicrobial resistance mechanisms leading to an MDR (resistant to three or more classes of agent) phenotype that further complicates treatment efforts. [1] [2] [3] [4] [5] [6] [7] 9, 10 Community-associated MRSA (CA-MRSA) and healthcareassociated MRSA (HA-MRSA), as well as macrolide resistance among b-haemolytic streptococci (BHS), complicate treatment of infection due to GPC in children and adults. 7, 9, 11 Because the USA has a high incidence of infections caused by CA-MRSA, vancomycin needs to be considered for empirical treatment of potential S. aureus infections. However, recent studies have reported increasing treatment failures against S. aureus isolates displaying elevated vancomycin MIC results (i.e. 1.5 mg/L) [12] [13] [14] [15] [16] that are still considered susceptible based on current breakpoints. 17, 18 Recommendations by IDSA suggest alternative therapeutic agents for the management of infections due to MRSA isolates with reduced susceptibility to vancomycin. 19 The emergence of such resistant bacterial species that are also particularly aggressive (e.g. CA-MRSA) highlights the need for further research to optimize treatment approaches and to develop new agents capable of dealing with these difficult infections. 7, 9, 11 Dalbavancin belongs to the lipoglycopeptide class of antimicrobial agents that act by interrupting bacterial cell wall synthesis resulting in bacterial death. 7, 11, [20] [21] [22] Dalbavancin was approved in the USA (2014) and Europe (2015) to treat adults with acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible isolates of S. aureus, including MRSA and MSSA, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group and vancomycin-susceptible Enterococcus faecalis. 23, 24 Dalbavancin allows for convenient parenteral administration, which can be a single dose of 1500 mg or a dose of 1000 mg followed by 500 mg a week later for treating ABSSSI. 23, 24 Dalbavancin is not licensed for use in paediatric patients, although it is potentially important in treating infections caused by highly resistant GPC in this population. 7, 11, [25] [26] [27] [28] Dalbavancin has demonstrated potent in vitro activity against S. aureus (including MRSA), streptococci and vancomycinsusceptible enterococci. 7, 11, [25] [26] [27] [28] In vitro activity has also been demonstrated against heterogeneous vancomycin-intermediate S. aureus (hVISA; MIC range 0.12-0.5 mg/L), vancomycinintermediate S. aureus (VISA; 0.5-2 mg/L) and other GPC less often recovered from human clinical specimens, including S. aureus isolates with decreased susceptibility to daptomycin (MIC 2 mg/L), telavancin (MIC 0.12 mg/L), teicoplanin (MIC 4 mg/L) and/or linezolid (MIC 8 mg/L). 26, 28, 29 Dalbavancin maintains activity against VanB-type strains of both E. faecalis and Enterococcus faecium. [20] [21] [22] Most of the published in vitro data concern the activity of dalbavancin against GPC from adult patients with ABSSSI. 23, 30, 31 The present report describes dalbavancin in vitro activity and potency when tested against a contemporary collection (2015-16) of GPC isolates responsible for a variety of clinical infections recovered from patient populations in US and European medical centres.
Materials and methods

Bacterial isolates
A total of 27 208 non-duplicate, consecutive clinical isolates were collected from the USA (85 sites, 16 690 isolates) and Europe (37 sites in 18 countries, 10 518 isolates). All organisms were isolated from documented infections and only one strain per patient infection episode was included in the surveillance collection. Isolates were derived from hospitalized patients with bloodstream infections (BSIs; 6649), skin and skin structure infections (SSSIs; 9855), pneumonias (7052), urinary tract infections (UTIs; 1217), intra-abdominal infections (914) and miscellaneous other infections (1521), according to a common surveillance design. 32 Species identification was performed at the participant medical centres and confirmed at the monitoring laboratory (JMI Laboratories, North Liberty, Iowa, USA) using the VITEK 2 System (bioMérieux, Hazelwood, MO, USA) and MALDI-TOF MS (Bruker, Billerica, MA, USA) when necessary.
Antimicrobial susceptibility testing
Isolates were susceptibility tested by broth microdilution following guidelines in the CLSI M07-A10 document 33 Dalbavancin against Gram-positive cocci from the USA and Europe JAC Table 1 . Antimicrobial activity of dalbavancin tested against the main organisms and organism groups of isolates Pfaller et al. Although not indicated for the treatment of infections due to E. faecium, the highest dalbavancin MIC value among vancomycinsusceptible E. faecium was only 0.25 mg/L (96.4% inhibited at 0.12 mg/L).
Dalbavancin was broadly active against the streptococci: The activity of dalbavancin was not adversely affected by resistance to other classes of agents that included oxacillin, clindamycin, erythromycin, levofloxacin, tetracycline or trimethoprim/sulfamethoxazole (Table 2 ). Whereas dalbavancin was not active against enterococci with a VanA phenotype, it was active (MIC 0.25 mg/L) against staphylococci with decreased susceptibility to vancomycin (MIC 2 mg/L). These results are consistent with in vitro surveillance studies reported since 2002 and cited in several recent reviews. 22, 27, 30, 31, [34] [35] [36] [37] [38] Dalbavancin MIC results for the years 2015-16 against US and European isolates of GPC remain consistent with previous results and do not indicate any shift in the MIC distributions or emerging resistances among the target pathogen groups.
This in vitro assessment of the activity of dalbavancin has some limitations, most importantly using local criteria to determine when GPC isolates such as CoNS and VGS are accepted as pathogens. We could determine that isolates were obtained from cultures of a specific site, but we were not able to identify other aspects of infection that would allow determination of clinical significance.
It is widely held that prolonged antimicrobial therapy is important in treating some infections due to GPC (for instance S. aureus BSI). 19 In those cases, an agent such as dalbavancin that can be administered once weekly may offer a significant advantage over current treatment regimens. 19, 22 Further studies to determine the efficacy and safety of dalbavancin in treating infections beyond ABSSSI are warranted.
In summary, dalbavancin demonstrated potent activity against contemporary Gram-positive pathogens from the USA and Europe.
